BioTech 365

OCTOBER 22, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Could cancer drugs address a hard-to-treat lung disease? Researchers say 2 look promising.Could cancer drugs address a hard-to-treat lung disease?

Research 40

Research Drugs 40

BioTech 365

APRIL 12, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: AACR: OncoMyx’s engineered rabbit pox virus shows promise in lung cancer model.AACR: OncoMyx’s engineered rabbit pox virus shows promise in lung cancer model aliu Sun, 04/11/2021 – … Continue reading → (..)

Engineer 40

Engineer Research 40

BioTech 365

NOVEMBER 1, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MIT team uncovers differences in T cells that drive immuno-oncology resistance in lung cancer.MIT team uncovers differences in T cells that drive immuno-oncology resistance in lung cancer … Continue reading →

Research 40

Research 40

BioTech 365

DECEMBER 3, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA.In

Research 40

Research 40

BioTech 365

SEPTEMBER 14, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: BridgeBio’s Navire preps SHP2 blocker for lung cancer trial after positive mouse study.BridgeBio’s Navire preps SHP2 blocker for lung cancer trial after positive mouse study arlene.weintraub Mon, … Continue reading (..)

Trials 40

Trials Research 40

BioTech 365

NOVEMBER 25, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Cancer-killing virus escapes immune destruction and fights metastatic lung tumors in mice.Cancer-killing virus escapes immune destruction and fights metastatic lung tumors in mice arlene.weintraub Wed, 11/25/2020 – … (..)

Research 40

Research 40

BioTech 365

SEPTEMBER 21, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ESMO: Iressa combined with Elevar’s EGFR drug boosts survival in early lung cancer use.ESMO: Iressa combined with Elevar’s EGFR drug boosts survival in early lung cancer use … Continue reading →

Drugs 40

Drugs Research 40

Pharma Times

NOVEMBER 7, 2023

Lung cancer is currently the leading cause of cancer deaths in the UK - News - PharmaTimes

100

100

BioTech 365

SEPTEMBER 21, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ESMO: Blueprint preps trial of drug targeting triple-mutant EGFR in lung cancer backed by mouse data.ESMO: Blueprint preps trial of drug targeting triple-mutant EGFR in lung cancer … Continue reading →

Trials 40

Trials Drugs Research 40

Drug Discovery World

APRIL 12, 2024

News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer. The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology.

Drugs 52

Drugs Genetic Engineering Immune Response Engineer 52

XTalks

SEPTEMBER 16, 2022

Researchers at the Francis Crick Institute and University College London in the UK have found how air pollution can trigger the activation of cells with existing genetic mutations to form cancer. Now, scientists have found a mechanism that may help explain how pollutants in the air can turn cells cancerous. Furthermore, inhaling PM 2.5

Research 97

Research Gene Scientist Biobanking 97

Drug Discovery World

MARCH 14, 2023

Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep – forming incurable secondary tumours. This exciting discovery brings us a step closer to understanding how we can slow down or stop the development of ER+ secondary breast cancer in the lung.

Research 98

Research Drugs Protein Scientist 98

pharmaphorum

NOVEMBER 25, 2022

The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea’s Hanmi Pharma, which originally developed the drug. Up to 4% of lung cancer cases have HER2 mutations, with HER2 exon 20 changes the most common form.

Drugs 96

Drugs FDA Approval Marketing Clinical Trials 96

Drug Discovery World

JANUARY 15, 2024

The acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumours. The announcement follows the news that Merck agreed a deal with Inspirna for colorectal cancer drug ompenaclid (RGX-202). “At

Clinical Development 105

Clinical Development Clinical Trials Clinical Trials Development 105

XTalks

APRIL 6, 2022

Lung cancer is the most common cancer in men and the third most common cancer in women, according to global lung cancer statistics by the World Cancer Research Fund. Around 85 percent of cases are non-small cell lung cancer (NSCLC). Photo source: Inivata.

DNA 105

DNA In-Vitro Doctors Doctor 105

World of DTC Marketing

JANUARY 4, 2022

(Stat News) Today, a study followed 380 patients being treated at community oncology groups across the U.S. after they were diagnosed with metastatic colon cancer. Patients who experience financial hardship during cancer treatment are at higher risk for treatment nonadherence, poor quality of life, and worse survival.

Pharma Companies 273

Pharma Companies Drugs Medicine Research 273

Drug Discovery World

FEBRUARY 23, 2024

The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). The post Combination therapy reduced risk of lung cancer progression by 38% appeared first on Drug Discovery World (DDW).

Trials 52

Trials Drugs 52

Drug Discovery World

JANUARY 26, 2024

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal, pancreatic and lung cancer and leukaemia.

Drugs 52

Drugs Trials Research Development 52

pharmaphorum

NOVEMBER 9, 2021

Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small cell lung cancer (NSCLC), making it the first country in the world to approve the routine use of the therapy in this setting.

HR 104

HR Licensing Licensing Medicine 104

Drug Discovery World

NOVEMBER 22, 2022

The National Institute for Health and Care Excellence (NICE) has published a positive recommendation for Takeda’s EXKIVITY (mobocertinib) for treating EGFR Exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy within a Final Appraisal Document (FAD). link] Accessed: November 2022.

Marketing 52

Marketing Medicine Drugs Production 52

Drug Discovery World

APRIL 28, 2023

News round-up for 24-28 April by DDW Digital Content Editor Diana Spencer. The stories cover the efforts by research teams to discover innovative novel drugs for geographic atrophy, HIV, lung cancer, anxiety and diabetes.

Drugs 52

Drugs Life Science Clinical Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 3, 2023

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer. As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. The post This week in drug discovery (30 January – 3 February) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs FDA Approval Development Manufacturing 52

Drug Discovery World

NOVEMBER 10, 2023

News round-up for 6-10 November by DDW Digital Content Editor Diana Spencer. With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is my round-up focus again.

Drugs 52

Drugs Genome Genomics Research 52

Drug Discovery World

OCTOBER 13, 2023

News round-up for 9-13 October by DDW Digital Content Editor Diana Spencer. The buzz with week has been around Phase I trials, with new therapies for lung cancer, geographic atrophy, Parkinson’s, sarcopenia and long Covid demonstrating positive early results or entering clinical trials for the first time.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Gene Therapy 52

Drug Discovery World

OCTOBER 20, 2023

News round-up for 16-20 October by DDW Digital Content Editor Diana Spencer. To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research opportunities and advances’, the news round-up this week highlights the latest developments in oncology drug discovery.

Drugs 59

Drugs Research Medicine Marketing 59

Drug Discovery World

SEPTEMBER 29, 2023

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. AACR Cancer Progress Report with spotlight on cancer immunotherapy On 13 September 2023, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2023: Advancing the Frontiers of Cancer Science and Medicine.

In-Vivo 52

In-Vivo Drugs Antibody Clinical Trials 52

Drug Discovery World

DECEMBER 9, 2022

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. million lung cancer project .

Drugs 52

Drugs Vaccination Vaccine Trials 52

Drug Discovery World

JULY 4, 2023

It was reported that the therapy demonstrated statistically significant improvement in progression-free survival vs docetaxel in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Antibody 52

Antibody Trials Engineer Drugs 52

Drug Discovery World

APRIL 21, 2023

News round-up for 16-21 April by DDW Digital Content Editor Diana Spencer. The news stories dominating the headlines this week have been the breaking developments in cancer drug discovery announced at the American Association of Cancer Research (AACR) Annual Meeting, which was held in Florida, US from 14-19 April.

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

pharmaphorum

JANUARY 19, 2021

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England. The post Scotland backs Roche’s Rozlytrek for ROS1 lung cancer appeared first on.

Medicine 85

Medicine Gene Drugs Production 85

pharmaphorum

MAY 7, 2021

The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast access to patients on England’s NHS. Guidance from NICE on Tagrisso (osimertinib) in this type of lung cancer is not due until September this year at the earliest.

Regulation 52

Regulation Medicine Production Trials 52

Drug Discovery World

SEPTEMBER 9, 2022

News round-up for 5-9 September by DDW Digital Content Editor Diana Spencer. Cancer research has been making headlines over the last seven days in the build-up to the European Society for Medical Oncology (ESMO) Congress 2022. This week’s top stories: Combination therapy halts lung cancer tumour growth in mice.

Drugs 52

Drugs Genetic Engineering Genetics Engineer 52

Drug Discovery World

APRIL 16, 2023

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

The Pharma Data

NOVEMBER 20, 2020

ALA: Lung Cancer Survival Has Increased Nationally to 22.6 20, 2020 — Lung cancer survival has increased to 22.6 percent nationally, and people of color face worse outcomes than White Americans, according to a report from the American Lung Association published online Nov. More News Resources.

Research 52

Research 52

Drug Discovery World

JULY 22, 2022

News round-up by DDW’s Reece Armstrong for 18 – 22 July. Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.? . New combination therapy shows promise against lung cancers? . Junk DNA could lead to cancer, study says

DNA 52

DNA Drugs Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 16, 2020

Use of Common Meds Tied to Lower Lung Cancer Mortality. 16, 2020 — Use of aspirin , metformin , and statins is associated with a lower risk for lung cancer mortality, according to a study published online Sept. Lung cancer mortality was similarly lower in a dose-dependent fashion with the use of aspirin and statins.

Research 52

Research Development Drugs 52

World of DTC Marketing

APRIL 14, 2022

Misinformation and trolls abound on every platform, often repeating FOX news lies. On lung cancer, I came across people recommending Chinese herbs for patients. According to STAT News, “Americans consume an unhealthy diet of health misinformation. This is today’s social media.

Branding 218

Branding Pharma Companies Containment Vaccination 218